Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Treatment Approaches for Patients With HER2+ mBC and Brain Metastases

November 16th 2023

Dr Joseph Gligorov discusses the management of brain metastases in patients with HER2-positive breast cancer, emphasizing tucatinib and trastuzumab as promising options.

Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

November 16th 2023

Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.

Dr Abdou on Sequencing CDK4/6 Inhibitors in HER2– Metastatic Breast Cancer

November 16th 2023

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Dr Jhaveri on Unanswered Questions in Breast Cancer Care

November 16th 2023

Komal Jhaveri, MD, FACP, discusses unmet needs for patients with breast cancer, as well as ways to address these needs through discussion and collaboration.

Dr Conlin on Targeting CNS Metastases in the Treatment of Breast Cancer

November 15th 2023

Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.

Dr Mamounas on Surgical De-Escalation Strategies in HER2+ Breast Cancers

November 15th 2023

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

Dr Bardia on the Continued Investigation of Elacestrant in ER+/HER2– Breast Cancer

November 15th 2023

Aditya Bardia, MD, MPH, discusses the continued investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast Cancer

November 15th 2023

Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.

Reviewing Best Practices in the Surgical Management of Breast Cancer: Traditional Approaches and Existing Challenges

November 14th 2023

In this second episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss the traditional surgical approaches that are utilized for patients with breast cancer and some of the challenges faced in those with later-stage disease.

Dr Haffty on Technical and Biological Advancements in Radiotherapy Within Breast Cancer

November 12th 2023

Bruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.

Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management

November 10th 2023

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer

November 10th 2023

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

TROP2-Targeting Antibody-Drug Conjugates

November 10th 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies

November 10th 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC

November 9th 2023

Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.

Treatment Sequencing Approaches for Patients With HER2+ mBC

November 9th 2023

Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.

Reviewing Best Practices in the Surgical Management of Breast Cancer: How Disease Stage Informs Treatment

November 7th 2023

In this first episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, explain how treatment approaches differ based on disease stage in patients with breast cancer.

FDA Awards Orphan Drug Designation to Rhenium Obisbemeda in Breast Cancer With Leptomeningeal Metastases

November 3rd 2023

The FDA has granted an orphan drug designation to rhenium obisbemeda as a potential therapeutic option for patients with breast cancer and leptomeningeal metastases.

Novel Therapies Under Investigation for HER2+ mBC

November 3rd 2023

Jane Meisel, MD, shares enthusiasm about upcoming trials and therapies in HER2+ metastatic breast cancer, with new antibody-drug conjugates showing promise.

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

November 3rd 2023

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.